Roseburia intestinalis inhibits interleukin-17 excretion and promotes regulatory T cells differentiation in colitis

Molecular Medicine Reports

Volumn 17, Issue 6, 2018, Pages 7567-7574

  Zhu, Changxin ^a,b   Song, Kerui ^a   Shen, Zhaohua ^a,b   Quan, Yongsheng ^a,b   Tan, Bei ^a,b   Luo, Weiwei ^a,b   Wu, Shuai ^a,b   Tang, Kai ^a,b   Yang, Zhenyu ^a,b   Wang, Xiaoyan ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Key Laboratory of Nonresolving Inflammation and Cancer   (China)

Author keywords

Inflammatory bowel disease; Interleukin 17; Microbiota; Regulatory T cells; Roseburia intestinalis

Indexed keywords

ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; DSMZ 14610; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; IL17A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL FLORA; BACTERIUM CULTURE; CELL DIFFERENTIATION; COLITIS; COLON MUCOSA; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; MALE; MONONUCLEAR CELL; MOUSE; NCM460 CELL LINE; NONHUMAN; OCCULT BLOOD; RADIOIMMUNOPRECIPITATION; REGULATORY T LYMPHOCYTE; ROSEBURIA INTESTINALIS; WESTERN BLOTTING; ANIMAL; CLOSTRIDIALES; DISEASE MODEL; IMMUNOLOGY; IMMUNOPHENOTYPING; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BIOMARKERS; CLOSTRIDIALES; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; INTERLEUKIN-17; INTESTINAL MUCOSA; MALE; MICE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 85046537041     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2018.8833     Document Type: Article

References (37)

1. Baumgart DC and Sandborn WJ: Crohn's disease. Lancet 380:1590-1605, 2012.
2. Danese S and Fiocchi C: Ulcerative colitis. N Engl J Med 365:1713-1725, 2011.
3. Ananthakrishnan AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:205-217, 2015.
4. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 390:2769-2778, 2018.
5. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M and Bernklev T; IBSEN Group: Work disability in inflammatory bowel disease patients 10 years after disease onset: Results from the IBSEN Study. Gut 62:368-375, 2013.
6. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, et al: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis 11:135-149, 2017.
7. Kaplan GG and Ng SC: Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152:313-321. e2, 2017.
8. Belkaid Y and Hand TW: Role of the microbiota in immunity and inflammation. Cell 157:121-141, 2014.
9. Blander JM, Longman RS, Iliev ID, Sonnenberg GF and Artis D: Regulation of inflammation by microbiota interactions with the host. Nat Immunol 18:851-860, 2017.
10. Caballero S and Pamer EG: Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol 33:227-256, 2015.
11. Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, Degnan PH, Booth CJ, Yu H and Goodman A: Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347:170-175, 2015.
12. Miyoshi J and Chang EB: The gut microbiota and inflammatory bowel diseases. Transl Res 179:38-48, 2017.
13. Eppinga H, Fuhler GM, Peppelenbosch MP and Hecht GA: Gut microbiota developments with emphasis on inflammatory bowel disease: Report from the Gut Microbiota for Health World Summit 2016. Gastroenterology 151:e1-e4, 2016.
14. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, et al: A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275-1283, 2014.
15. Tilg H and Danese S: Roseburia hominis: A novel guilty player in ulcerative colitis pathogenesis? Gut 63:1204-1205, 2014.
16. Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:329-342, 2014.
17. van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS and Rudensky AY: Memory of inflammation in regulatory T cells. Cell 166:977-990, 2016.
18. Himmel ME, Yao Y, Orban PC, Steiner TS and Levings MK: Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology 136:115-122, 2012.
19. Krieglstein CF, Cerwinka WH, Laroux FS, Grisham MB, Schürmann G, Brüwer M and Granger DN: Role of appendix and spleen in experimental colitis. J Surg Res 101:166-175, 2001.
20. Neurath MF, Fuss I, Kelsall BL, Stüber E and Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290, 1995.
21. Cua DJ and Tato CM: Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol 10:479-489, 2010.
22. Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P, Baldassano RN, Hyams JS, et al: Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis from colon-only Crohn's disease in treatment-naive pediatric patients. Gastroenterology 152:1345-1357. e7, 2017.
23. Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP and Powrie F: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208:1127-1133, 2011.
24. Vanhove W, Peeters PM, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De Schepper S, Van Lommel L, Reynaert NL, Schuit F, et al: Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm Bowel Dis 21:2673-2682, 2015.
25. Olsen J, Gerds TA, Seidelin JB, Csillag C, Bjerrum JT, Troelsen JT and Nielsen OH: Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis 15:1032-1038, 2009.
26. Sartor RB and Wu GD: Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152:327-339. e4, 2017.
27. Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G and Rescigno M: Probiotic and postbiotic activity in health and disease: Comparison on a novel polarised ex-vivo organ culture model. Gut 61:1007-1015, 2012.
28. Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, Chen H and Yu C: Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One 9:e109146, 2014.
29. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, et al: Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500:232-236, 2013.
30. Duncan SH, Hold GL, Barcenilla A, Stewart CS and Flint HJ: Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol 52:1615-1620, 2002.
31. Calderón-Gómez E, Bassolas-Molina H, Mora-Buch R, Dotti I, Planell N, Esteller M, Gallego M, Martí M, Garcia-Martín C, Martínez-Torró C, et al: Commensal-specific CD4 (+) cells from patients with Crohn's disease have a T-Helper 17 inflammatory profile. Gastroenterology 151:489-500. e3, 2016.
32. Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui T, Wei S, Liu Y, Wang Y, Vatan L, et al: Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. Oncoimmunology 5:e1105430, 2016.
33. Laidlaw BJ, Cui W, Amezquita RA, Gray SM, Guan T, Lu Y, Kobayashi Y, Flavell RA, Kleinstein SH, Craft J and Kaech SM: Production of IL-10 by CD4 (+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8 (+) T cells. Nat Immunol 16:871-879, 2015.
34. Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T, Rossmann P, Mrazek J, Kopecny J, Verdu EF and Tlaskalova-Hogenova H: Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol 163:250-259, 2011.
35. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ and Rudensky AY: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451-455, 2013.
36. Ding Y, Xu J and Bromberg JS: Regulatory T cell migration during an immune response. Trends Immunol 33:174-180, 2012.
37. Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, Panagiotou G and El-Nezami H: Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc NatlAcad Sci USA 113:e1306-E1315, 2016.